ReleaseWire Connect

TechNavio's analysts forecast the Global Heavy Construction Equipment market to grow at a CAGR of 8.76 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in infrastructural development activities. The Global Heavy Construction Equipment market has also been witnessing an increase in the adoption of retrofitted construction equipment. However, the high cost of construction equipment could pose a challenge to the growth of this market.

Global Markets Directs, 'Gastroesophageal (GE) Junction Carcinomas Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. Gastroesophageal (GE) Junction Carcinomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Global Markets Directs, 'Wet (Neovascular / Exudative) Macular Degeneration Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration. Wet (Neovascular / Exudative) Macular Degeneration Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Global Markets Directs, 'Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Global Markets Directs, 'Chemotherapy Induced Neutropenia Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia. Chemotherapy Induced Neutropenia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Global Markets Directs, 'Reperfusion Injury Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reperfusion Injury. Reperfusion Injury Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Global Markets Directs, 'Streptococcus Pneumoniae (Pneumococcus) Infections Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections. Streptococcus Pneumoniae (Pneumococcus) Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Global Markets Directs, 'Ulcers Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcers. Ulcers Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Global Markets Directs, 'Rhabdomyosarcoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Global Markets Directs, 'Chemotherapy Induced Nausea and Vomiting Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting. Chemotherapy Induced Nausea and Vomiting Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.